United States Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitors Market is expected to reach US$ 13.9 billion by 2032 | Top key players - Novartis AG, F. Hoffmann-La Roche Ltd, Amgen Inc.

Market Size and Growth:

The Global Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitors Market Size reached US$ 14.12 billion in 2024 and is expected to reach US$ 22.34 billion by 2033, growing at a CAGR of 5.9 % during the forecast period of 2025-2033. The Market growth is driven by the rising prevalence of cancer and increased adoption of targeted therapies that inhibit tumor angiogenesis. According to DataM Intelligence

Get a Free Sample Research PDF: https://datamintelligence.com/download-sample/vascular-endothelial-growth-factor-receptor-inhibitors-market?sz

The Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitors Market encompasses drugs that block VEGFR signaling pathways responsible for angiogenesis the formation of new blood vessels. These inhibitors are primarily used in treating cancers and ocular diseases by restricting tumor growth and abnormal vascularization, thereby controlling disease progression and improving therapeutic outcomes across oncology and ophthalmology applications.

Industry Recent Developments: United States

✅ November 2025: The U.S. market continues driving the global VEGFR inhibitors market through increased healthcare research and development investments, facilitating advanced diagnostic tools and personalized treatment plans using VEGFR inhibitors.

✅ October 2025: Fruquintinib, an oral small-molecule VEGFR1/2/3 inhibitor, developed by Hutchmed and Takeda, has seen notable recent developments, enhancing the treatment options for cancer with VEGFR inhibitors.

✅ June 2025 to October 2025: Increased adoption of combination therapies in the U.S. market targets advanced cancers, improving patient outcomes and supporting market growth due to the rising prevalence of cancer and related disorders.

Industry Recent Developments: Japan

✅ November 2025: Kuraray Co., Ltd. announced advancements related to VEGFR inhibitors, marking a key recent development in Japan's market.

✅ July 2025: Takeda Pharmaceutical began Phase 2 clinical trials of a VEGFR inhibitor focused on treating gastric cancer and other solid tumors prevalent in the Japanese population.

✅ June 2025: Chugai Pharmaceutical partnered with oncology hospitals in Japan to implement personalized VEGFR inhibitor therapies utilizing biomarker-driven treatment strategies.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/vascular-endothelial-growth-factor-receptor-inhibitors-market?sz

FDA Regulatory Decisions (2025):

✅ Rivoceranib (apatinib) + camrelizumab - NDA rejected (second CRL, Mar 21, 2025). The FDA declined to approve the rivoceranib + camrelizumab combo as first-line therapy for unresectable hepatocellular carcinoma (HCC); this was the second complete response letter (CRL) for that submission.
Context: the resubmission had previously been accepted with a PDUFA target date (March 20, 2025), but the agency issued a CRL instead.

✅ Tivozanib - recent NDA rejection for a new/expanded RCC indication (2025). Aveo/related sponsors received FDA feedback recommending an additional trial to address concerns about the data package submitted for the new indication. (Note: tivozanib / Fotivda has an earlier FDA approval for relapsed/refractory RCC from 2021; the 2025 action concerns a new submission/indication.)

✅ Cabozantinib / other VEGFR TKIs - label updates / pediatric/regulatory activity noted in 2025. Regulatory documents and agency summaries in 2025 reference cabozantinib activity and label/pediatric matters; cabozantinib remains an actively managed VEGFR-multi-kinase product in regulatory workflows. (See FDA/agency product notices and pediatric update listings).

European / EMA Activity (2024-2025):

✅ Rivoceranib - EMA orphan / pediatric dossier activity. The EMA granted orphan designation(s) related to rivoceranib combinations and the EMA PIP/waiver decisions are recorded (product-specific regulatory steps in 2024-2025 that affect future EU filings).

✅ General EMA oncology throughput in 2025. EMA continued to evaluate new cancer medicines and manage pediatric/ORPHAN designations - an environment that affects VEGFR combo/monotherapy filings. (See EMA newsletters / comparator reports summarizing 2024-mid-2025 activity.)

Mergers & Acquisitions in (2025):

✅ Elevar Therapeutics - business and licensing moves touching VEGFR pipeline positioning. Elevar (HLB affiliate), which holds rivoceranib rights in many territories, has been active with licensing deals and portfolio transactions (e.g., Elevar's global licensing deals and deals to acquire/obtain rights for targeted oncology assets in late-2024 / into 2025). Those corporate maneuvers shape who commercializes VEGFR assets and where regulatory submissions originate.

✅ Broader oncology M&A and deal environment (2025): 2025 saw a number of sizeable oncology/biotech M&A and licensing deals (major acquirers continuing to shore up oncology portfolios). While few blockbuster acquisitions in 2025 were VEGFR-exclusive, the general trend (large pharma buying oncology capabilities, plus mid-sized licensing deals) materially affects distribution, commercialization and subsequent regulatory strategy for VEGFR drugs. Representative industry roundups and deal lists cover the most relevant transactions.

✅ Exelixis and other VEGFR stakeholders - corporate activity. Large incumbents that market multi-kinase VEGFR inhibitors (cabozantinib, etc.) continued to report business development activity and licensing that can influence competitive positioning and lifecycle management.

Major Key Players:

Novartis AG
F. Hoffmann-La Roche Ltd
Amgen Inc.
Pfizer Inc.
Biocon
Exelixis, Inc.
Bayer AG
Eisai Co., Ltd.
Takeda Pharmaceuticals U.S.A., Inc.
Sanofi (Regeneron Pharmaceuticals, Inc.)
AVEO Pharmaceuticals, Inc.
Eli Lilly and Company
Genentech USA, Inc.

Segments Covered in the Vascular Endothelial Growth Factor Receptor Inhibitors Market:

By Type: VEGF-A, VEGF-B, VEGF-C, VEGF-D.

By Drug Type: Tyrosine Kinase Inhibitor (TKI), Monoclonal Antibody.

By Application: Advanced Renal Cell Carcinoma, Advanced Colorectal Cancer, Metastatic Colorectal Cancer (mCRC), Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Recurrent Glioblastoma (rGBM), Ovarian Cancer (OC), Hepatocellular Carcinoma, Thyroid cancer, Non-Small Cell Lung Cancer (NSCLC), Wet Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO), Others.

By Route of Administration: Oral, Intravenous, Intravitreal.

Regional Analysis for Vascular Endothelial Growth Factor Receptor Inhibitors Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Buy Now & Get 30% OFF - Grab 50% OFF on 2+ reports: https://www.datamintelligence.com/buy-now-page?report=vascular-endothelial-growth-factor-receptor-inhibitors-market

Chapter Outline:

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Vascular Endothelial Growth Factor Receptor Inhibitors market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Vascular Endothelial Growth Factor Receptor Inhibitors Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The global Vascular Endothelial Growth Factor Receptor Inhibitors market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Vascular Endothelial Growth Factor Receptor Inhibitors Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlimited Insights. One Subscription: https://www.datamintelligence.com/reports-subscription

Frequently asked questions:

➠ What is the global sales value, production value, consumption value, import and export of Vascular Endothelial Growth Factor Receptor Inhibitors market?

➠ Who are the global key manufacturers of the Vascular Endothelial Growth Factor Receptor Inhibitors Industry? How is their operating situation (capacity, production, sales, price, cost, gross, and revenue)?

➠ What are the Vascular Endothelial Growth Factor Receptor Inhibitors market opportunities and threats faced by the vendors in the global Vascular Endothelial Growth Factor Receptor Inhibitors Industry?

➠ Which application/end-user or product type may seek incremental growth prospects? What is the market share of each type and application?

➠ What focused approach and constraints are holding the Vascular Endothelial Growth Factor Receptor Inhibitors market?

➠ What are the different sales, marketing, and distribution channels in the global industry?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.